VivoSeq
Other

Williams Syndrome

4

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Williams syndrome is an early-stage landscape with 4 programs across 5 companies. The most active players are Novartis, Pfizer, Bristol-Myers Squibb. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2Pfizer logo

Pfizer

1 program

ApprovedBristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

ApprovedAlnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

PreclinicalAmgen logo

Amgen

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Completed5 · 83%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Clemastine Treatment in Individuals With Williams Syndrome
Active, not recruiting·SSheba Medical Center·Phase 2·NCT06087757·30 enrolled
Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome
Completed·QQilu Hospital of Shandong University·Phase 2·NCT06315699·28 enrolled
Buspirone Treatment of Anxiety in Williams Syndrome
Completed·MMassachusetts General Hospital·Phase 4·NCT04807517·20 enrolled
Vitamin D Metabolism and the Williams Syndrome
Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00013962
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank
Completed·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT02706639·305 enrolled
Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)
Completed·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT02692846·43 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)